The company is eyeing a launch for its IVD kits at the beginning of next year, as evidence grows for the integration of TMB analysis into the clinical care of cancer patients.
The firm presented on its pancreatic, breast, and prostate cancer programs, the latter of which is moving through clinical validation toward commercialization.
Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.
Participants shared data from head-to-head assay comparisons, reflected on the advancement of NGS and digital PCR methods, and discussed new standardization projects.
Representatives from industry, academia, the FDA, and insurance companies gathered for a joint FDA- and American Association for Cancer Research-sponsored workshop.
